Sign In

Communications of the ACM

ACM TechNews

NYC Brain Computer Startup Announces FDA Trial Before Elon Musk


View as: Print Mobile App Share: Send by email Share on reddit Share on StumbleUpon Share on Hacker News Share on Tweeter Share on Facebook
Synchron CEO Thomas Oxley with the tiny Stentrode device.

New York-based Synchron Inc. said it has received permission from the U.S. Food and Drug Administration to test its brain-computer interface device in human patients.

Credit Synchron

New York City-based brain-computer interface startup Synchron said the U.S. Food and Drug Administration has authorized human clinical trials for its commercial implant, ahead of Elon Musk's Neuralink company.

For the early feasibility study, Synchron intends to implant its Stentrode device in the brain to help paralyzed patients operate digital devices by thought; the device is implanted via a blood vessel at the base of the neck, and steered toward a vessel in the brain.

The Stentrode communicates with a second device in the chest through a tiny wire, then a transmitter sends signals to an external computer near the patient.

Synchron's Thomas Oxley said, "There are a range of safety concerns that haven't been dealt with before [in previous tests], including cybersecurity, which is a big part of the discussions we have been having."

From Bloomberg
View Full Article

 

Abstracts Copyright © 2021 SmithBucklin, Washington, DC, USA


 

No entries found